No there are no clincial trials as yet on brain metastatis as yet, but there have been trials on others, so the safety profile of the drug is well known (incl one recent one copied below). Other features of the drug combine to support the theory that it can be used in brain metastatis (can cross the blood brain barrier and transport other chemo drugs there too) and even elsewhere in the body can be used in combination with chemo or radiation - mifepristone makes the cancer cells more sensitive to killing by chemo or radiation as well as having some activity against cancer itself.
Completing 3 clinical trials after a patent is lodged takes 10-12 years before an application to the drug regulators can be made to have the drug approved for x treatment (in the interime it's classed as "experimental".
Nonetheless, the drug has been available on a compassionate use program for some time for those cancer patients who have exhausted other options etc. - that makes it a bit more difficult to obtain but not impossible.
However, the theory of it's potential effectiveness is based on the facts that:
1. mifepristone can cross the blood brain barrier (has been used effectively for meningiomas - benign brain tumours)
2. Studies demonstrate mifepristone works synergistically with chemo drugs and can negate multi-drug resistance in a wide variety of cancer cells
3. Studies show that it can enhance radiation treatments and make them more effective.
4. It has activity against a range of cancers (laboratory trials) eg. ovarian, cervical, lung etc
5. A case report below is also published on metastatic colon cancer which demonstrates that in a human trial (hence case report)- albeit only two people at this stage), the drug alone had activity against cancer cells, is well tolerated and in addition it's safety profile is well demonstrated as it's been used in patients for several years in meningioma.
1992: Mifepristone (RU 486) treatment of meningiomas.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&
- “Mifepristone treatment resulted in control of tumor growth (stable disease) in 6 of 10 patients who had shown recent evidence of tumor growth. In 3 of these 6 patients, consistent tumor shrinkage was seen. author's modified,”
2007: Synergistic effects of mifepristone on the cytotoxicity of cisplatin in cervical carcinoma cell lines and tumors grown in athymic mice
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=17
· “Our results suggest that mifepristone can improve the efficacy of cisplatin in cancer cells and this anti-hormonal drug therapy may be a candidate for further evaluation in combination with antineoplastic drugs in the treatment of cancer.”
Radiation Oncology Physicians:
http://www.mdanderson.org/departments/radiation/display.cfm? " target="_blank" rel="nofollow">http://www.mdanderson.org/departments/radiation/display.cfm?
· “.... We have found that breast cancer cells pretreated with RU486, an anti-progesterone, have increased sensitivity to killing with irradiation. The cellular mechanism and potential cross-talk with p53 and apoptotic pathways is currently being investigated.... “
http://www.mdanderson.org/departments/radiation/display.cfm? " target="_blank" rel="nofollow">http://www.mdanderson.org/departments/radiation/display.cfm?
· “.... We have found that breast cancer cells pretreated with RU486, an anti-progesterone, have increased sensitivity to killing with irradiation. The cellular mechanism and potential cross-talk with p53 and apoptotic pathways is currently being investigated.... “
2007: Evidence that progesterone receptor antagonists may help in the treatment of a variety of cancers by locally suppressing natural killer cell activity.
http://www.ncbi.nlm.nih.gov/pubmed/18225679?ordinalpos=18&am
2009 May;29
Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon – case report
http://www.ncbi.nlm.nih.gov/pubmed/19443374?ordinalpos=1&
BACKGROUND: Mifepristone, a progesterone receptor antagonist has been found to improve the length and quality of life in various spontaneous murine cancer models including tumors without progesterone receptors theoretically by inhibiting an immunomodulatory protein that suppresses natural killer cell function in the tumor microenvironment. MATERIALS AND METHODS: Mifepristone 200 mg per day by mouth was given to two patients with stage 4 colon cancer with extensive metastases. RESULTS: Both patients not only survived far longer than expected but had marked improvement in their quality of life similar to mice. Though the metastatic lesions did not disappear, no new ones appeared for a long time and the ones present did not grow. The drug was extremely well tolerated. CONCLUSION: The use of progesterone receptor antagonists may present a novel immunotherapy to help fight cancer. A larger controlled study is needed.